Valuation : RVL Pharmaceuticals plc

Market Cap 334K 288K 270K 246K 464K 31.94M 466K 3.2M 1.25M 16.12M 1.25M 1.23M 53.47M P/E 2021
-1.12x
P/E 2022 -1.95x
Enterprise Value 13.28M 11.44M 10.73M 9.79M 18.45M 1.27B 18.51M 127M 49.67M 641M 49.86M 48.78M 2.12B EV / Sales 2021
5.55x
EV / Sales 2022 2.49x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.19
5 years 0
Extreme 1.0E-6
3.71
10 years 0
Extreme 1.0E-6
9.9
Manager TitleAgeSince
Chief Operating Officer 44 31/12/2015
Human Resources Officer - 31/12/2015
Date Insider Type Main position Quantity % Market Cap.
19/10/23
Altchem Ltd.
SellCompany 14,122,659 12.6767%
19/10/23
Altchem Ltd.
SellCompany 14,122,659 12.6767%
18/10/23
Altchem Ltd.
SellCompany 3,421,537 3.0712%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 111
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.38%-0.95%+80.00%+115.26% 27.46B
Weighted average by Cap. -1.70%-1.06%+95.71%+133.63%

Financials

2021 2022
Net sales 17.5M 15.08M 14.14M 12.91M 24.32M 1.67B 24.39M 168M 65.45M 844M 65.71M 64.28M 2.8B 49.72M 42.84M 40.17M 36.67M 69.08M 4.75B 69.3M 477M 186M 2.4B 187M 183M 7.95B
Net income -64.92M -55.94M -52.45M -47.88M -90.2M -6.2B -90.49M -622M -243M -3.13B -244M -238M -10.39B -51.69M -44.54M -41.76M -38.12M -71.82M -4.94B -72.05M -495M -193M -2.49B -194M -190M -8.27B
Net Debt 7.2M 6.21M 5.82M 5.31M 10M 688M 10.04M 69.02M 26.93M 347M 27.04M 26.45M 1.15B 12.95M 11.16M 10.46M 9.55M 17.99M 1.24B 18.04M 124M 48.42M 625M 48.61M 47.55M 2.07B
Logo RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.
Employees
125
Date Price Change Volume
28/08/26 US$0.000001 0.00% 2,074
26/08/26 US$0.000001 0.00% 103
20/08/26 US$0.000001 0.00% 83,004
  1. Stock Market
  2. Stocks
  3. RVLPQ Stock